MD

Christopher W. DiGiovanni, MD, Installed as AOFAS® President

Friday, September 24, 2021 - 8:46pm

Rosemont, Ill., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeon, Christopher W. DiGiovanni, MD, has been named president of the American Orthopaedic Foot & Ankle Society (AOFAS) , the leading organization for lower extremity medicine and foot and ankle surgery.

Key Points: 
  • Rosemont, Ill., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Foot and ankle orthopaedic surgeon, Christopher W. DiGiovanni, MD, has been named president of the American Orthopaedic Foot & Ankle Society (AOFAS) , the leading organization for lower extremity medicine and foot and ankle surgery.
  • AOFAS allows us to grow as clinicians, researchers, and educators in a manner that directly impacts patients, said Dr. DiGiovanni.
  • The American Orthopaedic Foot & Ankle Society (AOFAS) mobilizes our dynamic community of foot and ankle orthopaedic surgeons to improve patient care through education, research, and advocacy.
  • By emphasizing collaboration and excellence, AOFAS inspires ever-increasing levels of professional performance leading to improved patient outcomes.

Julie Byerley, M.D. appointed President and Dean of Geisinger Commonwealth School of Medicine, Executive Vice President, Chief Academic Officer

Friday, September 24, 2021 - 7:29pm

DANVILLE, Pa., Sept. 24, 2021 /PRNewswire/ -- Geisinger announced that Julie Byerley, M.D., M.P.H., will serve as the new president and dean of the Geisinger Commonwealth School of Medicine (GCSOM), executive vice president and chief academic officer, effective January 1, 2022.

Key Points: 
  • DANVILLE, Pa., Sept. 24, 2021 /PRNewswire/ -- Geisinger announced that Julie Byerley, M.D., M.P.H., will serve as the new president and dean of the Geisinger Commonwealth School of Medicine (GCSOM), executive vice president and chief academic officer, effective January 1, 2022.
  • "I am thrilled to announce Julie Byerley as our school's next president and dean," said Jaewon Ryu, M.D., J.D., president and CEO of Geisinger.
  • "I'm honored and ecstatic to be joining as the new president and dean of GCSOM and Geisinger's chief academic officer," said Dr. Byerley.
  • Geisinger Commonwealth School of Medicine (Geisinger Commonwealth) is a member of the Geisinger family.

Johnstone Supply Approves Definitive Conversion Agreement with Redwood Capital Investments

Friday, September 24, 2021 - 6:07pm

Johnstone Supply, Inc. announced today that its members have approved a definitive conversion agreement with Redwood Capital Investments, LLC that will provide the capital required for Johnstone to convert its business structure from an Oregon Cooperative into a Delaware limited liability company operating under the name Johnstone Supply, LLC.

Key Points: 
  • Johnstone Supply, Inc. announced today that its members have approved a definitive conversion agreement with Redwood Capital Investments, LLC that will provide the capital required for Johnstone to convert its business structure from an Oregon Cooperative into a Delaware limited liability company operating under the name Johnstone Supply, LLC.
  • Pursuant to the terms of the agreement, Johnstone Supply LLC will continue to operate as a wholesale distributor based in Portland, exclusively providing products and services to the former members of the Johnstone Cooperative.
  • The 90+ individual Johnstone Business Owners are expected to execute exclusive territory distribution agreements with Johnstone Supply, LLC and will remain significant equity holders in the new entity.
  • We are very excited to welcome Redwood into the Johnstone family, commented Johnstone Chairman of the Board Jeffrey Sheehan.

WoodSpring Suites Eclipses 300 Open Hotels, Paving The Road For Future Growth

Friday, September 24, 2021 - 6:49pm

As of June 30, 2021, the WoodSpring Suites, MainStay Suites and Suburban Extended Stay brands each have 453, 217, and 86 hotels open or in the pipeline, respectively.

Key Points: 
  • As of June 30, 2021, the WoodSpring Suites, MainStay Suites and Suburban Extended Stay brands each have 453, 217, and 86 hotels open or in the pipeline, respectively.
  • "When the WoodSpring Suites brand was created, the overall awareness and the growth potential around the extended stay segment was very much in its infancy.
  • "Eclipsing 300 WoodSpring hotels is an incredible accomplishment and further validates Choice Hotels' strategic commitment to the segment.
  • There are 300 WoodSpring Suites hotels open in over 38 states and more than 100 in the pipeline across the U.S. as of June 30, 2021.

Shining a Light on the Healthcare Journey: Livanta Launches a New Publication for Medicare Beneficiaries, Their Families, and Other Caregivers

Friday, September 24, 2021 - 5:45pm

ANNAPOLIS JUNCTION, Md., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Livanta has created a new e-journal for Medicare patients, families, and other caregivers, The Livanta Beacon.

Key Points: 
  • ANNAPOLIS JUNCTION, Md., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Livanta has created a new e-journal for Medicare patients, families, and other caregivers, The Livanta Beacon.
  • This dynamic publication includes true-to-life stories about barriers and challenges that Medicare beneficiaries, family members, and other caregivers encountered, as told to Livanta staff.
  • The Livanta Beacon, which debuted on August 11, 2021, broadens Livanta's ability to outreach to beneficiaries and their families.
  • "Livanta understands that sharing patient stories is a significant way to engage with patients and their families.

Reven Holdings Announces Successful Completion of the First Part of RPI015 Clinical Trial Evaluating Its Lead Anti-sepsis Drug Candidate RJX in Hospitalized High-risk COVID-19 Patients

Friday, September 24, 2021 - 1:30pm

Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).

Key Points: 
  • Reven today announced the successful completion of Part 1 of the Two-Part, Two Cohort Multi-Center Phase I/II trial of Revens lead anti-sepsis drug candidate RJX in hospitalized high-risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • We will diligently advance the clinical development of RJX and evaluate its benefit for COVID-19 patients, said Fatih Uckun, MD PhD, the Chief Medical Officer of Reven.
  • It is currently being evaluated as a COVID-19 drug candidate in high risk COVID-19 patients (ClinicalTrials.gov Identifier: NCT04708340; https://clinicaltrials.gov/ct2/show/NCT04708340 ).
  • Reven Holdings, Inc., a Delaware corporation, through its Westminster, Colorado based operating company Reven, LLC, is a biopharmaceutical company.

Meet Dr. John Pittman, The Newest Aesthetic Expert at Goals Plastic Surgery

Friday, September 24, 2021 - 1:42pm

To meet the demand for procedures, Goals has been slowly adding to their team of ELITE, cosmetic surgeons and they would like to introduce their newest physician, Dr. John Pittman.

Key Points: 
  • To meet the demand for procedures, Goals has been slowly adding to their team of ELITE, cosmetic surgeons and they would like to introduce their newest physician, Dr. John Pittman.
  • Over the years, he has been called upon as an expert for several congressional panels on plastic surgery.
  • For more information on him, or Goals Plastic Surgery be sure to visit the website at GoalsPlasticSurgery.com today.
  • His passion for patients, and eye for aesthetics, saw Goals grow from a small practice in Brooklyn, NY, the most popular plastic surgery destination in NYC.

InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update

Friday, September 24, 2021 - 12:30pm

VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (InMed or the Company) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.
  • The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks.
  • Upon closing, InMed will become a global leader in the manufacturing of rare cannabinoids, with expertise in three distinct and complementary cannabinoid manufacturing approaches.
  • At June 30, 2021, the Companys total issued and outstanding shares were 8,050,707.

Pipestone Energy Corp. Announces Appointment of New Director, Distribution of Common Shares By Its Largest Shareholder Canadian Non-Operated Resources L.P. and Updated Investor Rights Arrangements

Friday, September 24, 2021 - 12:30pm

This news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.

Key Points: 
  • This news release contains certain information and statements (forward-looking statements) that constitute forward-looking information within the meaning of applicable Canadian securities laws.
  • All statements other than statements of current or historical fact constitute forward-looking statements.
  • The forward-looking statements contained herein reflect management's current views, but the assessments and assumptions upon which they are based may prove to be incorrect.
  • This press release includes references to financial measures commonly used in the oil and natural gas industry.

Artificial Intelligence Tool Improves Accuracy of Breast Cancer Imaging

Friday, September 24, 2021 - 12:00pm

"Our study demonstrates how artificial intelligence can help radiologists reading breast ultrasound exams to reveal only those that show real signs of breast cancer and to avoid verification by biopsy in cases that turn out to be benign," says study senior investigator Krzysztof Geras, PhD.

Key Points: 
  • "Our study demonstrates how artificial intelligence can help radiologists reading breast ultrasound exams to reveal only those that show real signs of breast cancer and to avoid verification by biopsy in cases that turn out to be benign," says study senior investigator Krzysztof Geras, PhD.
  • Some studies have shown that a majority of breast ultrasound exams indicating signs of cancer turn out to be noncancerous after biopsy.
  • Ten radiologists then each reviewed a separate set of 663 breast exams, with an average accuracy of 92 percent.
  • When aided by the AI model, their average accuracy in diagnosing breast cancer improved to 96 percent.